Effect of Leukoreduced Blood Transfusions on Infection Following Trauma

Completed · Phase 2/Phase 3

Conditions studied: Wounds and Injuries

In brief

The purpose of this study is to determine if leukoreduced blood transfusions reduce the risk of infection following trauma. Specifically, the investigators intend to evaluate whether there are clinically relevant differences in the rates of infection and in the severity of multiple organ failure in critically injured trauma patients receiving leukoreduced blood products compared to those receiving standard allogeneic blood products.

Key facts

Study ID

NCT00135291

Run by

University of Washington

People needed

300

Starts

2003-02-01

Expected to finish

2004-09-01

Last updated by the study team

2008-01-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Trauma patients
• Age > 17
• Transfusion within 24 hours of injury

You may not qualify if…

• Active infection at time of injury
• Anticipated survival of < 48 hours (e.g. gunshot wound [GSW] to head, cardiopulmonary resuscitation [CPR] in progress)
• Receipt of blood products for this injury event prior to randomization
• AB negative; B negative blood type.
• Positive antibody screen
• Prior requirement for irradiated, leukoreduced or cytomegalovirus (CMV) seronegative blood products
• Incarcerated
• Enrolled in pre-hospital trial

Where it is running

• Harborview Medical Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.